– Introduction –

This article summarizes some of the publicly disclosed high-quality medical asset projects from previous periods, covering six major categories of full-track technology platforms: AI pharmaceuticals, IVD diagnostics, RNA delivery, small molecule innovative drugs, CGT industrialization, and medical devices, each category including multiple high-quality medical assets. All assets feature clear technological differentiation, complete patent layout, and commercialization paths, fully adapting to enterprise pipeline expansion, BD licensing, project mergers and acquisitions, and due diligence needs for investment and financing.

(1) AI Pharmaceutical Digital Platform Direction:

1.1 AI Pharmaceuticals_Human Digital Simulation Platform

This project focuses on the high failure rates and long-cycle pain points of drug development. Its core asset is a high-precision digital human simulation platform built on 45 proprietary AI modules. Through digital twins of core systems such as human respiration, circulation, and metabolism, it conducts full simulation “stress tests” on candidate drug molecules during the laboratory phase to predict efficacy, toxicity, and metabolic pathways in advance. The technology is built on 11 years of complex system algorithm modeling experience, establishing an intellectual property system covering genomics, proteomics integration, and organ-level simulation. It holds over 100 authorized and pending patents, and its modular architecture can be adapted as needed to specific organs and disease fields.

The project has completed commercial adaptation readiness for 45 mature modules. Pharmaceutical-grade compatibility validation for core organs such as the liver and heart is underway, with the goal of completion within 2026; The platform is now capable of providing pharmaceutical companies with cloud-based “virtual lab” SaaS services and PoC collaborative development. The high failure rate of clinical trials caused by differences between animal models and human metabolism is the platform’s core alternative scenario—it can increase clinical trial success rates by about 30%, shorten R&D cycles by about 40%, and reduce single-drug R&D costs by more than 25%.

On the market side, the project covers the global demand for digital transformation in drug development, corresponding to hundreds of billions of dollars in efficiency improvement potential. The business model centers on SaaS subscriptions for small and medium-sized pharmaceutical companies, milestone-based paid PoC collaborations for large pharmaceutical companies, and provides intellectual property licensing for specific algorithm modules. It has already begun its Asian presence, with the first overseas subsidiary established and signing PoC agreements with multiple pharmaceutical companies. The team consists of experts in complex system modeling, AI technology leaders with backgrounds from major global companies, and clinical consultants from top medical schools. The core members have 11 years of experience in algorithm consulting and industry implementation. The next phase plans to launch a Series A financing round, leveraging its established patent pool and empirical data to enter the North American market, aiming to become an infrastructure-level platform for global drug development digitalization.

(2) IVD in vitro diagnostic directions:

2.1 IVD_ mass spectrometry detection technology

The project focuses on the long-standing bottleneck of China’s clinical mass spectrometry testing being monopolized by imports and the domestic production rate of less than 1%. Its core assets are the independently developed medical triple quadrupole liquid-mass spectrometry system and its supporting kit matrix. The technology is based on over thirty years of accumulated experience by the domestic mass spectrometer founding team, which has established full-stack self-developed capabilities covering ion sources, quadrupole mass analyzers, integrated devices, and AI-powered algorithms. It holds multiple original patents such as derivative-based sensitization, enabling detection sensitivity of certain metabolites by tens to thousands of times without hardware upgrades, achieving high-throughput detection performance for quantifying hundreds of metabolites in 15 minutes. The project has completed NMPA Class I filing and market launch for more than 13 clinical mass spectrometry kits, covering core testing varieties such as amino acids, catecholamines, vitamins, bile acids, neurotransmitters, and carnitine, and has provided clinical testing services in multiple top-tier hospitals. On the instrument side, the registration application for medical triple quadrupole mass spectrometers is underway, aiming to obtain the medical device registration certificate soon. Relying on an ecological layout of “instrument platform + supporting reagents + specialized services,” the project is dedicated to providing integrated clinical mass spectrometry solutions for hospital laboratories and third-party medical laboratories, addressing core pain points such as high import equipment purchase and maintenance costs, poor reagent compatibility, and supply chain constraints. On the market side, China’s clinical mass spectrometry market is expanding rapidly at a compound annual growth rate of nearly 10%. For example, the triple quadrupole equipment market size is expected to reach about 5.6 billion yuan by 2025, clearly indicating room for domestic substitution. The business model centers on instrument sales and financial leasing, with continuous supply of kits and cloud service value-added services as long-term sources of income. The first target customers are laboratory departments of domestic top-tier hospitals and large independent medical laboratories. The team is composed of nationally recognized leading metabolomics scientists, founders of mass spectrometry instruments in China, and an industry management team with experience in commercializing large-scale pharmaceuticals, possessing a complete capability chain from hardware R&D and methodology development to clinical translation. This round of financing aims to accelerate the certification of core instruments and the market promotion of reagent kits, establishing a leading position during the critical window period of policy promotion of domestic substitution of high-end scientific instruments.

2.2 IVD_ Fully Homogeneous Chemiluminescence Diagnostic Platform

The core asset of this project is the domestically pioneering “cage-shaped nanomolecular probe” fully homogeneous chemiluminescence technology platform. Unlike traditional magnetic particle chemiluminescence, this technology achieves a detection path without magnetic beads, requires no cleaning, and is light-excited, making it one of the few domestic innovations currently comparable in performance to Roche electrochemiluminescence. The project aims to address the pain points of profitability pressure in the IVD industry under centralized procurement through technological iteration, aiming to become a technological leader in the domestic immunodiagnostics field.

Key Highlights:

1. Proven underlying technological innovation to build a dimensionality reduction cost advantage o Extreme cost reduction: Completely eliminates expensive magnetic particles and separation cleaning solutions at the reagent side, reducing material costs by more than 30% compared to traditional methods; On the instrument side, since there is no need for magnetic separation modules or complex liquid circuits, BOM costs and failure rates are significantly reduced. Even after the centralized procurement halved entry prices, the project still maintained a high gross profit margin of over 70%, with profitability resilience far exceeding that of traditional manufacturers. o Performance benchmark gold standard: Consistency data with Roche electrochemiluminescence shows R² > 0.99; reagent CV value controlled at 3%-8%, far below the industry average of 10%-15%. At the same time, because the luminescence process is controlled, it supports multiple repeated measurements of a single sample, solving the clinical pain point where traditional acridine ester luminescence can only be detected in a single test.

2. A mature and comprehensive commercialization matrix and strong channel monetization capabilities o Existing cash flow foundation: The project is not an early-stage R&D concept. Currently, 18 tumor marker reagents and 300-speed instruments have been certified and launched for sale, with over 10 customers having installed them with excellent feedback. New menus for thyroid function, myocardial markers, and more are being registered, and the 1600-speed ultra-high-speed prototype is about to roll off the production line. o Deep customer and channel heritage: Relying on the parent company’s more than 20 years of IVD industry experience, the project boasts a mature nationwide distribution network with nearly 700 active existing customers (including public hospitals, health checkup centers, and third-party testing institutions). This existing channel advantage can greatly shorten the market cultivation period for new products, offering a 2-3 year first-mover landing window compared to startups, enabling immediate scaling upon installation.

3. High-barrier patent moat and scarce policy endorsements: o The project has filed 16 invention patents (6 granted) centered on core probes and detection systems, building a technical barrier that is difficult to replicate. o Recognized and funded by government support such as the “Nanjing Life and Health Science and Technology Special Project” and “Liaoning Province Key R&D Project,” and owns an R&D and production base of about 4,000㎡, with an annual reagent production capacity of over 700 million yuan for testing.

China’s immunodiagnostics market is about 40 billion yuan, with chemiluminescence being the most barrier-to-market and the lowest localization rate (about 40%). Driven by the normalization of centralized procurement, the market urgently needs iterative technologies with extreme cost-effectiveness. Relying on the differentiated advantages of “high throughput (up to 1600 speed) + low cost + high performance,” the project precisely entered the window of domestic substitution. Financing Needs: This round plans to raise 30 to 50 million yuan, mainly to accelerate registration and certification of new reagents such as thyroid and myocardial drugs, launch production of ultra-high-throughput instruments, and supplement sales and operating funds, supporting rapid scaling up of existing mature product maturities.

(3) RNA & Targeted Delivery Technology Directions:

3.1 RNA drug _siRNA pipelines and extrahepatic delivery platforms

The project focuses on RNA drug development and has formed a layout of “clinical assets + extrahepatic delivery platform + subsequent pipeline reserves.” Its core clinical asset is a GalNAc-siRNA targeting TTR, used for ATTR-CM and ATTR-PN, which has entered Phase I clinical trials in China and is expected to obtain FDA orphan drug designation in 2025. Existing first-person data have confirmed its solid PK/PD and safety foundation, with the target dosing regimen of subcutaneous injection every 6 months, balancing long-term treatment adherence with commercial acceptability. Core patents have completed PCT and China deployment, with patent protection periods covering 2044–2045. The second layer of value comes from the extrahepatic delivery platform. The company has established capabilities in RNA sequence design, chemical modification, and AI-assisted optimization, while simultaneously advancing fat tissue and skeletal muscle delivery. In fat delivery, over 70% of target genes have been knocked down under single-dose low-dose administration, and the DIO model has shown clear weight loss effects, showing potential for extension to metabolic indications; In the direction of skeletal muscle delivery, after a single dose, multiple skeletal muscle pieces achieved about 75% sustained gene knockdown, demonstrating strong tissue selectivity. This means the project is not limited to a single ATTR asset, but is building a next-generation RNA delivery capability that can continue to be replicated. On the pipeline side, the company continues to expand around cardiovascular, metabolic, and kidney fields. Several projects are in the pre-discovery to IND stage, with plans to submit five INDs by 2027 and advance two key projects into IND-enabling. The team possesses comprehensive capabilities from RNA discovery, delivery, CMC to clinical development, and relies on a mature industry system to promote transformation. The current project simultaneously features clinical-stage assets, a differentiated platform, and a continuously expanding pipeline, offering both single-project advancement value and space for platform cooperation and subsequent transaction extensions.

3.2 Delivery Platform_Central Nervous System Nucleic Acid Nano Delivery Platform

The project focuses on the high-barrier scenario of central nervous system drug delivery, centered on a programmable delivery platform based on nucleic acid nanostructured particles, capable of carrying DNA, RNA, proteins, and small molecule drugs, with a focus on solving issues such as low delivery efficiency in deep brain and spinal cord tissues, insufficient load compatibility, and difficulties in immunogenicity control. The platform uses short-stranded DNA as its base material, achieving selective tissue delivery through programmable design of morphology, structure, and size, while balancing degradability and in vivo safety. It is suitable for neurodegenerative diseases, brain tumors, and other challenging central system indications. Its existing layout covers brain delivery, spinal cord delivery, brain tumors, and triple-negative breast cancer, forming a multi-path structure of “platform + self-developed pipeline + collaborative development + authorized output.” The platform’s value is mainly reflected in its central delivery capability and payload versatility. Existing data have confirmed its distribution advantage in the deep brain parenchyma. Head-to-head comparison shows that nucleic acid drugs delivered by the platform can penetrate deep into tissues below the brain surface, whereas the control technology’s distribution in the brain rapidly declines with depth; In the ALS transgenic mouse model, the delivery performance of the 25ug vector was superior to that of 100ug free nucleic acid drugs, demonstrating higher delivery efficiency and better drug utilization. The platform supports nucleic acid drugs, small molecules, and protein loadings, offering the capability to serve as a universal delivery foundation, serving CNS drug R&D as well as a synergistic module for existing partner assets. The team has published milestone papers in the field of nucleic acid self-assembly and delivery, supported by the National Key R&D Program and the Ministry of Natural Science and Technology of China, providing a foundation for continuous iteration and research transformation. The project is currently in the preclinical stage, with a relatively complete early validation closed loop: the underlying platform has completed mechanism construction, with key directions advanced in rodent and non-human primates pre-stage, and the first CNS project has received clear efficacy signals. For investors, these assets have the opportunity to become a universal foundation in the central delivery sector, which can be valued through self-developed development or amplified commercial value through joint development and licensing. The central nervous system has long been one of the most challenging delivery stages in innovative drug development. If the platform continues to verify deep tissue coverage, safety, and multipayload compatibility, it will have strong potential for collaboration and transaction expansion.

3.3 Exosomes _RNA Delivery and Clinical Exosome Drugs

The project focuses on central nervous system drug delivery and has formed a dual-layer layout of “natural exosome drugs + RNA delivery platform + subsequent indication expansion.” At the front, there is already a natural exosome drug direction, advancing around scenarios such as severe pulmonary inflammation, acute exacerbation of COPD, stroke, Alzheimer’s disease, Parkinson’s disease, and heart failure. Some areas have already accumulated human case data and IIT data; The rear end builds a central RNA delivery chassis around engineered biological vesicles, aiming to address key bottlenecks such as the difficulty of RNA drugs crossing the blood-brain barrier, insufficient effective distribution in the brain, and poor long-term feasibility of dosaging. The platform’s core highlight lies in balancing loading capacity, brain delivery capability, and long-term drug delivery scenarios. The existing delivery system can accommodate siRNA, mRNA, circular RNA, and gene editing loads, and has been validated for multi-RNA coloading and longer fragment loading capabilities; Intracranial data have shown that the average load per single vesicle is high, functional intracranial knockdown can reach 40%–60%, and it possesses strong neuronal delivery capacity. In terms of drug delivery routes, the company is also developing non-invasive methods such as nasal delivery, which are more suitable for managing chronic CNS diseases. In the short term, natural exosome drugs can provide a driving force for clinical and regulatory advancement; In the medium to long term, RNA delivery platforms have the potential to accumulate into more replicable underlying capabilities. On the drug side, early human validation has already been conducted in areas such as severe inflammation and heart failure. CMC, separation processes, and scale-up production have also entered the stage of cooperation and licensing discussions with overseas companies; On the platform side, it corresponds to the long-standing high-barrier track of central RNA drugs, supporting both self-development and external cooperation and licensing. The company has begun discussions with overseas exosome companies on CMC, separation processes, scale-up production, and licensing cooperation. The clinical drug and platform delivery lines can correspond respectively to proximal transformation and medium- to long-term platform extension. The Series A financing scale ranges from 50 million to 100 million RMB, focusing on clinical advancement, GMP capacity building, and expansion of RNA delivery platforms.

3.4 Delivery Platform_eCIS Programmable protein delivery platform

The project focuses on efficient intracellular targeted delivery of biological macromolecules, centered on a novel programmable vector modified with eCIS devices that can efficiently deliver proteins and other biological macromolecules to specific cells. The platform is derived from a natural delivery system. Through rational design and engineering modification, it has developed a delivery tool that combines cell recognition, transmembrane injection, and load protection capabilities, focusing on solving the problem of large molecules such as protein drugs, gene editing tools, and transcription factors that cannot efficiently enter the cell interior. The platform has established underlying independent intellectual property rights, completed domestic patent applications and PCT layout, and is positioning potential applications in gene therapy, tumor targeting, gene editor delivery, transcription factor delivery, stem cell differentiation, and in vitro delivery. The platform’s advantages mainly lie in two layers of “programmability.” First, the tail fibers of eCIS can be reprogrammed to enable vectors to recognize specific cells, improving delivery specificity; Second, the loading protein can be programmed to accommodate different functional tasks on the same platform. Existing research has systematically clarified the complete structure, loading, and delivery mechanisms of eCIS, with related findings published in Cell, Science China Life Sciences, and Science Advances. Compared to mainstream routes such as AAV/viral delivery and LNP, the platform differentiates itself in specificity, safety, load size, and programmability, while also offering lower production costs and strong load compatibility, with proven protein load ranges of 10–200 kDa. In animal experiments, the platform demonstrated high safety and low immunogenicity, laying the foundation for subsequent pharmaceutical development. The project is still in the early platform validation stage but is highly proactive: the core team comes from the forefront of pathogen biology and delivery system research, has been one of the earliest and systematic international reports on the structure of eCIS and its drug loading and delivery mechanism, and has completed modification validation targeting human cell delivery. As gene editing, protein drugs, and cell therapies continue to expand, the value of delivery platforms increasingly depends on specificity, compatibility, and engineering. The platform already has original mechanisms, early patents, and a foundation for multi-scenario adaptation. Going forward, it can advance through three paths: tool platform collaboration, incubation of self-developed treatment projects, and external licensing.

All the above projects are open to diverse cooperation, sincerely inviting investment institutions, pharmaceutical companies, and industry platforms to connect and exchange!

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.